The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents
oleh: Chiara Tarantelli, Lu Zhang, Elisabetta Curti, Eugenio Gaudio, Filippo Spriano, Valdemar Priebe, Luciano Cascione, Alberto J. Arribas, Emanuele Zucca, Davide Rossi, Anastasios Stathis, Francesco Bertoni
| Format: | Article |
|---|---|
| Diterbitkan: | Ferrata Storti Foundation 2019-07-01 |
Deskripsi
No description available for this item.